GenSight Biologics reports positive long-term visual acuity gains and safety results from Phase I/II Study of GS010 for the treatment of Leber Hereditary Optic Neuropathy (LHON)

GenSight Biologics to Participate in Multiple Conferences in November

GenSight Biologics Reports its Cash Position as of September 30, 2017

GenSight Biologics Appoints Barrett Katz as Chief Medical Officer

GenSight Biologics to Present Data on GS010 and GS030 at the 2017 Congress of the European Society of Gene & Cell Therapy

GenSight Biologics to Attend Chardan Gene Therapy Conference

GenSight Biologics integrates the Enternext® PEA-PME 150 index

GenSight Biologics integrates the CAC® Small, CAC® Mid and Small and CAC® All-Tradable Euronext indexes

GenSight Biologics Completes Enrollment of RESCUE Phase III Study of GS010 in the treatment of Leber’s Hereditary Optic Neuropathy

GenSight Biologics Reports Interim Financial Results for the First Half of 2017